OX40 Ligand/TNFSF4 Antibody (182601) [Alexa Fluor® 647]

• Reactivity: Mu
• Applications: WB, B/N
• Clone: 182601
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor 647

OX40 Ligand/TNFSF4 Antibody (182601) [Alexa Fluor® 647] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse OX40 Ligand/TNFSF4
  Gln49-Leu198
  Accession # P43488
• Specificity: Detects mouse OX40 Ligand/TNFSF4 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human (rh) APRIL, rhGITR Ligand, rhLIGHT, rhLT alpha 1/ beta 2, rhLT alpha 2/ beta 1, recombinant cotton rat TNF‑ alpha , recombinant mo
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Neutralization
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for OX40 Ligand/TNFSF4 Antibody (182601) [Alexa Fluor® 647]

• CD134 ligand
• CD134L
• CD252 antigen
• CD252
• Glycoprotein Gp34
• gp34
• OX40 antigen ligand
• OX40 Ligand
• OX40L
• OX-40L
• OX4OL
• TAX transcriptionally-activated glycoprotein 1
• tax-transcriptionally activated glycoprotein 1 (34kD)
• tax-transcriptionally activated glycoprotein 1, 34kD
• TNFSF4
• tumor necrosis factor (ligand) superfamily, member 4
• tumor necrosis factor ligand superfamily member 4
• TXGP1

Background

OX40 Ligand (OX40L), also known as gp34, is a type II transmembrane glycoprotein belonging to the TNF superfamily. Murine OX40L cDNA encodes a 198 amino acid (aa) protein comprised of a 28 aa N-terminal cytoplasmic domain, a 20 aa transmembrane segment, and a 150 aa C-terminal extracellular domain (1). Human and mouse OX40L share 46% sequence identity at the amino acid level (1). OX40L is expressed on activated antigen presenting cells such as B cells, macrophages, dendritic cells, and on endothelial cells at the site of inflammation. The receptor for OX40L is OX40 (CD134) which is expressed predominantly on activated CD4⁺ T cells. Expression of OX40 is transient following engagement of T cell receptors (2). Ligation of OX40L by OX40 stimulates proliferation and differentiation of activated B cells, and increases immunoglobulin secretion (3, 4). The expression of OX40L on B cells is upregulated by CD40 ligation (3). Engagement of the OX40‑OX40L system has co-stimulatory effects on T cells by stimulating the production of cytokines by T helper cells and increasing the survival of memory T cells (2, 5). Blocking of the OX40‑OX40L interaction in vitro inhibits co-stimulation resulting in decreased T cell proliferation and adhesion of T cells to endothelial cells. Inhibition of the OX40‑OX40L interaction in disease models has beneficial effects in acute graft-versus-host disease, inflammatory bowel disease and decreases the development of collagen-induced arthritis and experimental leishmaniasis (6).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.